All Pharma News
Bristol Myers Squibb completes acquisition of Forbius

Bristol Myers Squibb completes acquisition of Forbius
PHARMABIZ
22 Sep 2020
Share Share
Bristol Myers Squibb Completes Acquisition of Forbius

Bristol Myers Squibb Completes Acquisition of Forbius
BUSINESSWIRE
21 Sep 2020
Share Share
BMS agrees to acquire biotherapeutics developer Forbius

BMS agrees to acquire biotherapeutics developer Forbius
PHARMACEUTICALTECHNOLOGY
25 Aug 2020
Share Share
Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta

Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta
BIOSPACE
24 Aug 2020
Share Share
Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta

Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta
BUSINESSWIRE
24 Aug 2020
Share Share
Forbius Completes Phase 1 Oncology Dose-Escalation with AVID200

Forbius Completes Phase 1 Oncology Dose-Escalation with AVID200
BUSINESSWIRE
08 Nov 2019
Share Share
Forbius Completes Enrollment into Phase 1a Solid Tumor Trial of AVID200

Forbius Completes Enrollment into Phase 1a Solid Tumor Trial of AVID200
BUSINESSWIRE
14 Oct 2019
Share Share
Forbius: Phase 2 Clinical Data with Tumor-Selective Anti-EGFR ADC AVID100

Forbius: Phase 2 Clinical Data with Tumor-Selective Anti-EGFR ADC AVID100
BUSINESS WIRE
11 Oct 2019
Share Share
Forbius: First Patient Dosed in a Phase 1b Myelofibrosis Trial of AVID200

Forbius: First Patient Dosed in a Phase 1b Myelofibrosis Trial of AVID200
BUSINESSWIRE
24 Apr 2019
Share Share
Forbius Announces First Patient Dosed in Ph2a EGFR-Overexpressing (TNBC)

Forbius Announces First Patient Dosed in Ph2a EGFR-Overexpressing (TNBC)
BUSINESSWIRE
23 Apr 2019
Share Share